Vaccine efficacy

Overview of vaccine efficacy

Fluzone, a type of influenza vaccine

Vaccine efficacy refers to the percentage reduction of disease in a vaccinated group of people compared to an unvaccinated group under optimal conditions. It is a measure used to determine how effective a vaccine is at preventing a specific disease. Vaccine efficacy is typically assessed in clinical trials before a vaccine is approved for public use.

Calculation of vaccine efficacy

Vaccine efficacy is calculated using the following formula:

\( VE = \frac{(ARU - ARV)}{ARU} \times 100 \%

where:

• \( VE \) is the vaccine efficacy,
• \( ARU \) is the attack rate in the unvaccinated group,
• \( ARV \) is the attack rate in the vaccinated group.

This formula provides the percentage reduction in disease incidence among the vaccinated group compared to the unvaccinated group.

Factors affecting vaccine efficacy

Several factors can influence the efficacy of a vaccine, including:

• Age of the recipient: Some vaccines may be less effective in older adults or very young children.
• Immune status: Individuals with compromised immune systems may not respond as well to vaccines.
• Viral mutations: Changes in the virus, such as those seen in influenza, can affect how well a vaccine works.
• Vaccine storage and handling: Improper storage can reduce vaccine potency.

Vaccine effectiveness

While vaccine efficacy is measured under controlled clinical trial conditions, vaccine effectiveness refers to how well a vaccine performs in the real world. Effectiveness can be influenced by factors such as population demographics, vaccine coverage, and the presence of circulating virus strains.

Importance of vaccine efficacy

Understanding vaccine efficacy is crucial for public health planning and decision-making. High efficacy vaccines can lead to herd immunity, reducing the spread of infectious diseases within a community. This is particularly important for diseases with high transmission rates.

Related pages

• Vaccine
• Herd immunity
• Clinical trial
• Influenza vaccine